Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) EPS (Weighted Average and Diluted) (2016 - 2026)

Mimedx's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at -$0.07 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 240.0% to -$0.07 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.2, a 25.93% decrease, with the full-year FY2025 number at $0.32, up 14.29% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.07 in Q1 2026 for Mimedx, down from $0.1 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for MDXG hit a ceiling of $0.37 in Q4 2023 and a floor of -$0.11 in Q1 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.04 across 5 years, with a median of $0.05 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 266.67% in 2022 and later surged 1100.0% in 2024.
  • Tracing MDXG's EPS (Weighted Average and Diluted) over 5 years: stood at $0.07 in 2022, then soared by 428.57% to $0.37 in 2023, then plummeted by 86.49% to $0.05 in 2024, then skyrocketed by 100.0% to $0.1 in 2025, then crashed by 170.0% to -$0.07 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for MDXG at -$0.07 in Q1 2026, $0.1 in Q4 2025, and $0.11 in Q3 2025.